



(11) **EP 2 969 002 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61P 29/00 ^(2006.01) **A61K 31/47** ^(2006.01)
A61K 31/495 ^(2006.01) **A61P 11/00** ^(2006.01)
A61P 9/10 ^(2006.01)

(48) Corrigendum issued on:
21.02.2018 Bulletin 2018/08

(86) International application number:
PCT/US2014/021706

(45) Date of publication and mention
of the grant of the patent:
10.01.2018 Bulletin 2018/02

(87) International publication number:
WO 2014/164282 (09.10.2014 Gazette 2014/41)

(21) Application number: **14779507.4**

(22) Date of filing: **07.03.2014**

(54) **USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY**

VERWENDUNG VON LEVOCETIRIZIN UND MONTELUKAST ZUR BEHANDLUNG
TRAUMATISCHER VERLETZUNGEN

UTILISATION DE LEVOCETIRIZINE ET MONTELUKAST DANS LE TRAITEMENT DE BLESSURE
TRAUMATIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Zacco Sweden AB**
P.O. Box 5581
114 85 Stockholm (SE)

(30) Priority: **13.03.2013 US 201361780336 P**

(56) References cited:
WO-A1-2011/159821 WO-A1-2013/012199
WO-A2-2011/041462 WO-A2-2012/064301
US-A1- 2013 030 000 US-A9- 2012 040 892

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(60) Divisional application:
17205910.7

- **Yu GI ET AL: "Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. - PubMed - NCBI", , 1 January 2005 (2005-01-01), XP055289974, Retrieved from the Internet:
URL:<http://www.ncbi.nlm.nih.gov/pubmed/15452361?dopt=Abstract> [retrieved on 2016-07-20]**

(73) Proprietor: **Inflammatory Response Research, Inc.**
Santa Barbara CA 93103 (US)

(72) Inventor: **MAY, Bruce, Chandler**
Santa Barbara, CA 93111 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 969 002 B8